{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T19:34:26Z","timestamp":1792092866615,"version":"4.4.0"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002701","name":"Ministry of Education","doi-asserted-by":"publisher","award":["HZKY20220473"],"award-info":[{"award-number":["HZKY20220473"]}],"id":[{"id":"10.13039\/501100002701","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Shandong Province Natural Science Foundation","doi-asserted-by":"publisher","award":["ZR2023MB080"],"award-info":[{"award-number":["ZR2023MB080"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmaceutical Science Advances"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.pscia.2026.100125","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T07:05:09Z","timestamp":1779433509000},"page":"100125","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Therapeutic potential of the sphingosine kinase 2 inhibitor opaganib"],"prefix":"10.1016","volume":"4","author":[{"given":"Fuxun","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujuan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueyang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingbo","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peilu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4526-714X","authenticated-orcid":false,"given":"Bo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.pscia.2026.100125_bib1","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s10620-007-0133-6","article-title":"Suppression of ulcerative colitis in mice by orally available inhibitors of sphingosine kinase","volume":"53","author":"Maines","year":"2008","journal-title":"Dig. Dis. Sci."},{"issue":"1","key":"10.1016\/j.pscia.2026.100125_bib2","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1124\/jpet.109.163444","article-title":"Pharmacology and antitumor activity of ABC294640, a selective inhibitor of Sphingosine Kinase-2","volume":"333","author":"French","year":"2010","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"11","key":"10.1016\/j.pscia.2026.100125_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115793","article-title":"A comprehensive review: sphingolipid metabolism and implications of disruption in sphingolipid homeostasis","volume":"22","author":"Quinville","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.pscia.2026.100125_bib4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrc.2017.96","article-title":"Sphingolipid metabolism in cancer signalling and therapy","volume":"18","author":"Ogretmen","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"22","key":"10.1016\/j.pscia.2026.100125_bib5","doi-asserted-by":"crossref","first-page":"36898","DOI":"10.18632\/oncotarget.16370","article-title":"Mammalian sphingosine kinase (SphK) isoenzymes and isoform expression: challenges for SphK as an oncotarget","volume":"8","author":"Hatoum","year":"2017","journal-title":"Oncotarget"},{"issue":"13","key":"10.1016\/j.pscia.2026.100125_bib6","doi-asserted-by":"crossref","first-page":"5509","DOI":"10.1021\/jm4011687","article-title":"Importance of sphingosine Kinase (SphK) as a target in developing cancer therapeutics and recent developments in the synthesis of novel SphK inhibitors","volume":"57","author":"Plano","year":"2014","journal-title":"J. Med. Chem."},{"issue":"6","key":"10.1016\/j.pscia.2026.100125_bib7","doi-asserted-by":"crossref","first-page":"8455","DOI":"10.1007\/s13277-015-4700-8","article-title":"Sphingosine kinase 2 promotes colorectal cancer cell proliferation and invasion by enhancing MYC expression","volume":"37","author":"Zhang","year":"2016","journal-title":"Tumor Biol."},{"key":"10.1016\/j.pscia.2026.100125_bib22","doi-asserted-by":"crossref","DOI":"10.1186\/s13046-015-0205-y","article-title":"Targeting sphingosine kinase 2 (SphK2) by ABC294640 inhibits colorectal cancer cell growth in vitro and in vivo","volume":"34","author":"Xun","year":"2015","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.pscia.2026.100125_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16091779","article-title":"Opaganib downregulates N-Myc expression and suppresses in vitro and in vivo growth of neuroblastoma cells","volume":"16","author":"Maines","year":"2024","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.pscia.2026.100125_bib13","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1182\/blood-2014-03-559385","article-title":"Inhibition of sphingosine kinase 2 downregulates the expression of c-Myc and Mcl-1 and induces apoptosis in multiple myeloma","volume":"124","author":"Venkata","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.pscia.2026.100125_bib24","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2021.598218","article-title":"SphK2\/S1P promotes metastasis of triple-negative breast cancer through the PAK1\/LIMK1\/Cofilin1 signaling pathway","volume":"8","author":"Shi","year":"2021","journal-title":"Front. Mol. Biosci."},{"issue":"10","key":"10.1016\/j.pscia.2026.100125_bib25","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1002\/ijc.31234","article-title":"The sphingosine kinase 2 inhibitor ABC294640 displays anti-non-small cell lung cancer activities in vitro and in vivo","volume":"142","author":"Dai","year":"2018","journal-title":"Int. J. Cancer"},{"issue":"15","key":"10.1016\/j.pscia.2026.100125_bib10","doi-asserted-by":"crossref","first-page":"20080","DOI":"10.18632\/oncotarget.7914","article-title":"Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells","volume":"7","author":"Ding","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.pscia.2026.100125_bib9","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1158\/1535-7163.MCT-13-0466","article-title":"Targeting sphingosine kinase induces apoptosis and tumor regression for KSHV-associated primary effusion lymphoma","volume":"13","author":"Qin","year":"2014","journal-title":"Mol. Cancer Therapeut."},{"issue":"16","key":"10.1016\/j.pscia.2026.100125_bib26","doi-asserted-by":"crossref","first-page":"4683","DOI":"10.7150\/jca.46269","article-title":"Targeting sphingosine kinase by ABC294640 against diffuse intrinsic pontine glioma (DIPG)","volume":"11","author":"Dai","year":"2020","journal-title":"J. Cancer"},{"issue":"2","key":"10.1016\/j.pscia.2026.100125_bib27","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s00277-022-05056-7","article-title":"Phase I study of opaganib, an oral sphingosine kinase 2-specific inhibitor, in relapsed and\/or refractory multiple myeloma","volume":"102","author":"Kang","year":"2023","journal-title":"Ann. Hematol."},{"issue":"2","key":"10.1016\/j.pscia.2026.100125_bib28","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.bbrc.2018.02.075","article-title":"Targeting sphingosine kinase 2 by ABC294640 inhibits human skin squamous cell carcinoma cell growth","volume":"497","author":"Zhou","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.pscia.2026.100125_bib29","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.bbrc.2016.05.102","article-title":"Inhibition of ceramide glucosylation sensitizes lung cancer cells to ABC294640, a first-in-class small molecule SphK2 inhibitor","volume":"476","author":"Guan","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"1","key":"10.1016\/j.pscia.2026.100125_bib30","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.pharep.2013.08.014","article-title":"Inhibition of sphingosine kinase-2 ablates androgen resistant prostate cancer proliferation and survival","volume":"66","author":"Gestaut","year":"2014","journal-title":"Pharmacol. Rep."},{"issue":"7","key":"10.1016\/j.pscia.2026.100125_bib31","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1258\/ebm.2012.012028","article-title":"Sphingosine kinase isoforms as a therapeutic target in endocrine therapy resistant luminal and basal-A breast cancer","volume":"237","author":"Antoon","year":"2012","journal-title":"Exp. Biol. Med."},{"issue":"1","key":"10.1016\/j.pscia.2026.100125_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053521","article-title":"Inhibition of Sphingosine Kinase-2 in a murine model of Lupus nephritis","volume":"8","author":"Snider","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.pscia.2026.100125_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/s41420-023-01320-5","article-title":"Nuclear SPHK2\/S1P induces oxidative stress and NLRP3 inflammasome activation via promoting p53 acetylation in lipopolysaccharide-induced acute lung injury","volume":"9","author":"Gong","year":"2023","journal-title":"Cell Death Discov."},{"issue":"7","key":"10.1016\/j.pscia.2026.100125_bib34","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofac232","article-title":"Opaganib in coronavirus disease 2019 pneumonia: results of a randomized, placebo-controlled phase 2a trial","volume":"9","author":"Winthrop","year":"2022","journal-title":"Open Forum Infect. Dis."},{"issue":"5","key":"10.1016\/j.pscia.2026.100125_bib35","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/bph.17393","article-title":"S1P\/S1PRs-TRPV4 axis is a novel therapeutic target for persistent pain and itch in chronic dermatitis","volume":"182","author":"Zhang","year":"2025","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.pscia.2026.100125_bib36","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1007\/s10753-018-0795-6","article-title":"SPHK-2 promotes the particle-induced inflammation of RAW264.7 by maintaining consistent expression of TNF-\u03b1 and IL-6","volume":"41","author":"Yang","year":"2018","journal-title":"Inflammation"},{"issue":"4","key":"10.1016\/j.pscia.2026.100125_bib37","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25042322","article-title":"The sphingolipid-modulating drug opaganib protects against radiation-induced lung inflammation and fibrosis: potential uses as a medical countermeasure and in cancer radiotherapy","volume":"25","author":"Maines","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pscia.2026.100125_bib38","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.antiviral.2018.08.010","article-title":"Transient inhibition of sphingosine kinases confers protection to influenza A virus infected mice","volume":"158","author":"Xia","year":"2018","journal-title":"Antivir. Res."},{"issue":"21","key":"10.1016\/j.pscia.2026.100125_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232113191","article-title":"Opaganib protects against radiation toxicity: implications for homeland security and antitumor radiotherapy","volume":"23","author":"Maines","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pscia.2026.100125_bib40","doi-asserted-by":"crossref","first-page":"323","DOI":"10.2147\/IJNRD.S386396","article-title":"The sphingosine kinase 2 inhibitor opaganib protects against acute kidney injury in mice","volume":"15","author":"Maines","year":"2022","journal-title":"Int. J. Nephrol. Renovascular Dis."},{"issue":"6","key":"10.1016\/j.pscia.2026.100125_bib41","doi-asserted-by":"crossref","first-page":"594","DOI":"10.2340\/00015555-3160","article-title":"Inhibiting sphingosine kinase 2 Derived-sphingosine-1-phosphate ameliorates psoriasis-like skin disease via blocking Th17 differentiation of naive CD4 T lymphocytes in mice","volume":"99","author":"Shin","year":"2019","journal-title":"Acta Derm. Venereol."},{"key":"10.1016\/j.pscia.2026.100125_bib42","doi-asserted-by":"crossref","DOI":"10.1038\/emi.2015.61","article-title":"Sphingosine kinase 2 is a chikungunya virus host factor co-localized with the viral replication complex","volume":"4","author":"Reid","year":"2015","journal-title":"Emerg. Microb. Infect."},{"issue":"7","key":"10.1016\/j.pscia.2026.100125_bib8","doi-asserted-by":"crossref","first-page":"678","DOI":"10.4161\/cbt.11.7.14903","article-title":"Targeting NF\u03baB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2","volume":"11","author":"Antoon","year":"2011","journal-title":"Cancer Biol. Ther."},{"issue":"12","key":"10.1016\/j.pscia.2026.100125_bib11","doi-asserted-by":"crossref","first-page":"2744","DOI":"10.1158\/1535-7163.MCT-15-0279","article-title":"The sphingosine kinase 2 inhibitor ABC294640 reduces the growth of prostate cancer cells and results in accumulation of dihydroceramides in vitro and in vivo","volume":"14","author":"Venant","year":"2015","journal-title":"Mol. Cancer Therapeut."},{"issue":"12","key":"10.1016\/j.pscia.2026.100125_bib12","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1158\/1541-7786.MCR-14-0626","article-title":"Downregulation of critical oncogenes by the selective SK2 inhibitor ABC294640 hinders prostate cancer progression","volume":"13","author":"Schrecengost","year":"2015","journal-title":"Mol. Cancer Res."},{"issue":"10","key":"10.1016\/j.pscia.2026.100125_bib14","doi-asserted-by":"crossref","first-page":"2803","DOI":"10.1158\/0008-5472.CAN-13-2732","article-title":"Sphingosine kinase 2 promotes acute lymphoblastic leukemia by enhancing MYC expression","volume":"74","author":"Wallington-Beddoe","year":"2014","journal-title":"Cancer Res."},{"issue":"37","key":"10.1016\/j.pscia.2026.100125_bib15","doi-asserted-by":"crossref","first-page":"60181","DOI":"10.18632\/oncotarget.11112","article-title":"Suppression of c-Myc and RRM2 expression in pancreatic cancer cells by the sphingosine kinase-2 inhibitor ABC294640","volume":"7","author":"Lewis","year":"2016","journal-title":"Oncotarget"},{"issue":"3\u20134","key":"10.1016\/j.pscia.2026.100125_bib16","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000323911","article-title":"Experimental osteoarthritis in rats is attenuated by ABC294640, a selective inhibitor of Sphingosine Kinase-2","volume":"87","author":"Fitzpatrick","year":"2011","journal-title":"Pharmacology"},{"issue":"11","key":"10.1016\/j.pscia.2026.100125_bib17","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1167\/iovs.05-1236","article-title":"Pharmacologic manipulation of sphingosine kinase in retinal endothelial cells: implications for angiogenic ocular diseases","volume":"47","author":"Maines","year":"2006","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"issue":"1","key":"10.1016\/j.pscia.2026.100125_bib18","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1186\/s12964-024-01626-6","article-title":"Signaling controversy and future therapeutical perspectives of targeting sphingolipid network in cancer immune editing and resistance to tumor necrosis factor-\u03b1 immunotherapy","volume":"22","author":"Sukocheva","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.pscia.2026.100125_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2019.107464","article-title":"Sphingosine kinase and sphingosine-1-phosphate receptor signaling pathway in inflammatory gastrointestinal disease and cancers: a novel therapeutic target","volume":"207","author":"Sukocheva","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.pscia.2026.100125_bib20","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.2147\/DDDT.S367612","article-title":"Recent progress in the development of opaganib for the treatment of Covid-19","volume":"16","author":"Smith","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"issue":"9","key":"10.1016\/j.pscia.2026.100125_bib21","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms12091767","article-title":"Effect of opaganib on supplemental oxygen and mortality in patients with severe SARS-CoV-2 based upon FIO2 requirements","volume":"12","author":"Neuenschwander","year":"2024","journal-title":"Microorganisms"},{"issue":"7","key":"10.1016\/j.pscia.2026.100125_bib43","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc2875","article-title":"Sphingosine 1-phosphate and cancer","volume":"10","author":"Pyne","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.pscia.2026.100125_bib44","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.3390\/curroncol30030231","article-title":"Inhibition of sphingosine kinase 2 results in PARK2-Mediated mitophagy and induces apoptosis in multiple myeloma","volume":"30","author":"Wu","year":"2023","journal-title":"Curr. Oncol."},{"issue":"19","key":"10.1016\/j.pscia.2026.100125_bib45","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221910767","article-title":"The sphingosine kinase 2 inhibitor ABC294640 restores the sensitivity of BRAFV600E mutant Colon cancer cells to vemurafenib by reducing AKT-mediated expression of Nucleophosmin and translationally-controlled tumour protein","volume":"22","author":"Grbcic","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.pscia.2026.100125_bib46","doi-asserted-by":"crossref","first-page":"524","DOI":"10.4161\/cbt.11.5.14677","article-title":"Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts","volume":"11","author":"Beljanski","year":"2014","journal-title":"Cancer Biol. Ther."},{"issue":"5","key":"10.1016\/j.pscia.2026.100125_bib47","doi-asserted-by":"crossref","first-page":"744","DOI":"10.14740\/wjon1890","article-title":"Targeting SNAI1-Mediated colorectal cancer chemoresistance and stemness by sphingosine kinase 2 inhibition","volume":"15","author":"Janakiraman","year":"2024","journal-title":"World J. Oncol."},{"issue":"23","key":"10.1016\/j.pscia.2026.100125_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242316901","article-title":"Opaganib (ABC294640) induces immunogenic tumor cell death and enhances checkpoint antibody therapy","volume":"24","author":"Maines","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pscia.2026.100125_bib49","series-title":"Sphingolipids in Cancer","first-page":"295","article-title":"Targeting sphingosine kinases for the treatment of cancer","author":"Lewis","year":"2018"},{"issue":"5","key":"10.1016\/j.pscia.2026.100125_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16051050","article-title":"Combined antitumor effect of the serine protease urokinase inhibitor upamostat and the sphingosine kinase 2 inhibitor opaganib on Cholangiocarcinoma patient-derived xenografts","volume":"16","author":"Asumda","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.pscia.2026.100125_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2018.00631","article-title":"Targeting sphingosine kinase isoforms effectively reduces growth and survival of neoplastic mast cells with D816V-KIT","volume":"9","author":"Bandara","year":"2018","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.pscia.2026.100125_bib52","first-page":"546","article-title":"Targeting sphingosine kinase 2 suppresses cell growth and synergizes with BCL2\/BCL-XL inhibitors through NOXA-mediated MCL1 degradation in cholangiocarcinoma","volume":"9","author":"Ding","year":"2019","journal-title":"Am. J. Cancer Res."},{"issue":"11","key":"10.1016\/j.pscia.2026.100125_bib53","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1210\/en.2010-0420","article-title":"Antiestrogenic effects of the novel sphingosine Kinase-2 Inhibitor ABC294640","volume":"151","author":"Antoon","year":"2010","journal-title":"Endocrinology"},{"issue":"7","key":"10.1016\/j.pscia.2026.100125_bib54","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1002\/cam4.1543","article-title":"The combination of a sphingosine kinase 2 inhibitor (ABC294640) and a Bcl-2 inhibitor (ABT-199) displays synergistic anti-myeloma effects in myeloma cells without a t(11;14) translocation","volume":"7","author":"Sundaramoorthy","year":"2018","journal-title":"Cancer Med."},{"issue":"4","key":"10.1016\/j.pscia.2026.100125_bib55","doi-asserted-by":"crossref","DOI":"10.3892\/ol.2022.13231","article-title":"Potential of a sphingosine 1-phosphate receptor antagonist and sphingosine kinase inhibitors as targets for multiple myeloma treatment","volume":"23","author":"Tanaka","year":"2022","journal-title":"Oncol. Lett."},{"issue":"13","key":"10.1016\/j.pscia.2026.100125_bib56","doi-asserted-by":"crossref","first-page":"16663","DOI":"10.18632\/oncotarget.7693","article-title":"Proteasomal degradation of sphingosine kinase 1 and inhibition of dihydroceramide desaturase by the sphingosine kinase inhibitors, SKi or ABC294640, induces growth arrest in androgen-independent LNCaP-AI prostate cancer cells","volume":"7","author":"McNaughton","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.pscia.2026.100125_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103625","article-title":"Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase","volume":"72","author":"Lin","year":"2021","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.pscia.2026.100125_bib58","doi-asserted-by":"crossref","first-page":"169","DOI":"10.14740\/wjon1768","article-title":"Sphingosine-1-Phosphate inhibition increases endoplasmic reticulum stress to enhance Oxaliplatin sensitivity in pancreatic cancer","volume":"15","author":"Gao","year":"2024","journal-title":"World J. Oncol."},{"key":"10.1016\/j.pscia.2026.100125_bib59","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.2147\/OTT.S208519","article-title":"Sphingosine kinase 2 inhibitor ABC294640 displays anti-epithelial ovarian cancer activities in vitro and in vivo","volume":"12","author":"Song","year":"2019","journal-title":"OncoTargets Ther."},{"issue":"8","key":"10.1016\/j.pscia.2026.100125_bib60","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1080\/15384047.2015.1056944","article-title":"ABC294640, a sphingosine kinase 2 inhibitor, enhances the antitumor effects of TRAIL in non-small cell lung cancer","volume":"16","author":"Yang","year":"2015","journal-title":"Cancer Biol. Ther."},{"issue":"2","key":"10.1016\/j.pscia.2026.100125_bib61","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.18632\/oncotarget.23415","article-title":"The sphingosine kinase 2 inhibitor ABC294640 inhibits cervical carcinoma cell growth","volume":"9","author":"Xu","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.pscia.2026.100125_bib62","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.00694","article-title":"Targeting SphK2 reverses acquired resistance of regorafenib in hepatocellular carcinoma","volume":"10","author":"Shi","year":"2020","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.pscia.2026.100125_bib63","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2415","article-title":"Sphingosine-1-phosphate related signalling pathways manipulating virus replication","volume":"33","author":"Zhang","year":"2023","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.pscia.2026.100125_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.bios.2020.112752","article-title":"COVID-19 diagnosis - a review of current methods","volume":"172","author":"Y\u00fcce","year":"2021","journal-title":"Biosens. Bioelectron."},{"issue":"4","key":"10.1016\/j.pscia.2026.100125_bib65","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.plipres.2013.05.001","article-title":"Biological functions of sphingomyelins","volume":"52","author":"Slotte","year":"2013","journal-title":"Prog. Lipid Res."},{"issue":"10","key":"10.1016\/j.pscia.2026.100125_bib66","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-023-06154-8","article-title":"Autophagy: regulator of cell death","volume":"14","author":"Liu","year":"2023","journal-title":"Cell Death Dis."},{"issue":"8","key":"10.1016\/j.pscia.2026.100125_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22084067","article-title":"Pharmacological modulators of autophagy as a potential strategy for the treatment of COVID-19","volume":"22","author":"Pereira","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.pscia.2026.100125_bib68","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.bbagen.2016.11.033","article-title":"Dihydroceramide desaturase inhibitors induce autophagy via dihydroceramide-dependent and independent mechanisms","volume":"1861","author":"Casasampere","year":"2017","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"issue":"12","key":"10.1016\/j.pscia.2026.100125_bib69","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.biocel.2012.08.025","article-title":"Dihydroceramide delays cell cycle G1\/S transition via activation of ER stress and induction of autophagy","volume":"44","author":"Gagliostro","year":"2012","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"6","key":"10.1016\/j.pscia.2026.100125_bib70","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1080\/15548627.2020.1761651","article-title":"The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells","volume":"17","author":"Mu\u00f1oz-Guardiola","year":"2021","journal-title":"Autophagy"},{"issue":"12","key":"10.1016\/j.pscia.2026.100125_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2021.103437","article-title":"Dihydroceramide desaturase promotes the formation of intraluminal vesicles and inhibits autophagy to increase exosome production","volume":"24","author":"Wu","year":"2021","journal-title":"iScience"},{"issue":"21","key":"10.1016\/j.pscia.2026.100125_bib72","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21218371","article-title":"A novel selective sphingosine kinase 2 inhibitor, HWG-35D, ameliorates the severity of imiquimod-induced psoriasis model by blocking Th17 differentiation of naive CD4 T lymphocytes","volume":"21","author":"Shin","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.pscia.2026.100125_bib73","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.drudis.2021.11.002","article-title":"The PI3K\/Akt\/mTOR pathway: a potential pharmacological target in COVID-19","volume":"27","author":"Basile","year":"2022","journal-title":"Drug Discov. Today"},{"issue":"1","key":"10.1016\/j.pscia.2026.100125_bib74","doi-asserted-by":"crossref","first-page":"L45","DOI":"10.1152\/ajplung.00124.2020","article-title":"Is targeting Akt a viable option to treat advanced-stage COVID-19 patients?","volume":"319","author":"Somanath","year":"2020","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"issue":"1","key":"10.1016\/j.pscia.2026.100125_bib75","doi-asserted-by":"crossref","DOI":"10.1038\/s41420-020-00331-w","article-title":"The role of death domain proteins in host response upon SARS-CoV-2 infection: modulation of programmed cell death and translational applications","volume":"6","author":"Ivanisenko","year":"2020","journal-title":"Cell Death Discov."},{"issue":"1","key":"10.1016\/j.pscia.2026.100125_bib76","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41580-021-00418-x","article-title":"Mechanisms of SARS-CoV-2 entry into cells","volume":"23","author":"Jackson","year":"2022","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"3","key":"10.1016\/j.pscia.2026.100125_bib77","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/bjh.16530","article-title":"Sphingosine kinase-2 is overexpressed in large granular lymphocyte leukaemia and promotes survival through Mcl-1","volume":"190","author":"LeBlanc","year":"2020","journal-title":"Br. J. Haematol."},{"issue":"6","key":"10.1016\/j.pscia.2026.100125_bib78","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed antiviral drugs for Covid-19-Interim WHO solidarity trial results","volume":"384","author":"Pan","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.pscia.2026.100125_bib79","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s10555-020-09880-z","article-title":"Glycosylation and raft endocytosis in cancer","volume":"39","author":"Johannes","year":"2020","journal-title":"Cancer Metastasis Rev."},{"issue":"24","key":"10.1016\/j.pscia.2026.100125_bib80","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242417303","article-title":"The implication of sphingolipids in viral infections","volume":"24","author":"Thomas","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.pscia.2026.100125_bib81","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/cr.2008.15","article-title":"SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway","volume":"18","author":"Wang","year":"2008","journal-title":"Cell Res."},{"issue":"16","key":"10.1016\/j.pscia.2026.100125_bib82","doi-asserted-by":"crossref","first-page":"8030","DOI":"10.1128\/JVI.00870-08","article-title":"Influenza virus infection augments NK cell inhibition through reorganization of major histocompatibility complex class I proteins","volume":"82","author":"Achdout","year":"2008","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.pscia.2026.100125_bib83","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0228735","article-title":"Glucosylceramide synthase maintains influenza virus entry and infection","volume":"15","author":"Drews","year":"2020","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.pscia.2026.100125_bib84","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006316","article-title":"A role for glycolipid biosynthesis in severe fever with thrombocytopenia syndrome virus entry","volume":"13","author":"Drake","year":"2017","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.pscia.2026.100125_bib85","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202101168","article-title":"Elevation in sphingolipid upon SARS-CoV-2 infection: possible implications for COVID-19 pathology","volume":"5","author":"Vitner","year":"2022","journal-title":"Life Sci. Alliance"},{"issue":"22","key":"10.1016\/j.pscia.2026.100125_bib86","doi-asserted-by":"crossref","first-page":"8107","DOI":"10.1073\/pnas.1324197111","article-title":"Genesis and pathogenesis of the 1918 pandemic H1N1 influenza A virus","volume":"111","author":"Worobey","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"1","key":"10.1016\/j.pscia.2026.100125_bib87","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-020-0147-3","article-title":"Ebola virus disease","volume":"6","author":"Jacob","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.pscia.2026.100125_bib88","first-page":"435","article-title":"Ebola virus: pathogenesis and countermeasure development","volume":"vol. 6","author":"Furuyama","year":"2019"},{"key":"10.1016\/j.pscia.2026.100125_bib89","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.pharmthera.2016.09.008","article-title":"Targeting sphingosine-1-phosphate signaling in lung diseases","volume":"168","author":"Ebenezer","year":"2016","journal-title":"Pharmacol. Ther."},{"issue":"9","key":"10.1016\/j.pscia.2026.100125_bib90","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/j.bbalip.2019.05.008","article-title":"Sphingosine kinase 2 is a negative regulator of inflammatory macrophage activation","volume":"1864","author":"Weigert","year":"2019","journal-title":"Biochim. Biophys. Acta Mol. Cell Biol. Lipids"},{"issue":"2","key":"10.1016\/j.pscia.2026.100125_bib91","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.bbrc.2012.01.103","article-title":"Sphingosine 1-phosphate (S1P)\/S1P receptor 1 signaling regulates receptor activator of NF-\u03baB ligand (RANKL) expression in rheumatoid arthritis","volume":"419","author":"Takeshita","year":"2012","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"10416","key":"10.1016\/j.pscia.2026.100125_bib92","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1016\/S0140-6736(23)01525-8","article-title":"Rheumatoid arthritis","volume":"402","author":"Di Matteo","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.pscia.2026.100125_bib93","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23020905","article-title":"Rheumatoid arthritis: pathogenic roles of diverse immune cells","volume":"23","author":"Jang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"2","key":"10.1016\/j.pscia.2026.100125_bib94","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10787-010-0060-6","article-title":"Attenuation of arthritis in rodents by a novel orally-available inhibitor of sphingosine kinase","volume":"19","author":"Fitzpatrick","year":"2010","journal-title":"Inflammopharmacology"},{"issue":"10023","key":"10.1016\/j.pscia.2026.100125_bib95","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(15)00149-X","article-title":"Atopic dermatitis","volume":"387","author":"Weidinger","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.pscia.2026.100125_bib96","doi-asserted-by":"crossref","first-page":"L379","DOI":"10.1152\/ajplung.00010.2008","article-title":"Animal models of acute lung injury","volume":"295","author":"Matute-Bello","year":"2008","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"10.1016\/j.pscia.2026.100125_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2020.109861","article-title":"Role of sphingosine 1-phosphate signalling in tissue fibrosis","volume":"78","author":"Donati","year":"2021","journal-title":"Cell. Signal."},{"issue":"3","key":"10.1016\/j.pscia.2026.100125_bib98","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s12013-021-01022-8","article-title":"Sphingolipids as a novel therapeutic target in radiation-induced lung injury","volume":"79","author":"Jacobson","year":"2021","journal-title":"Cell Biochem. Biophys."},{"issue":"2","key":"10.1016\/j.pscia.2026.100125_bib99","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.canlet.2015.04.016","article-title":"Radiation triggering immune response and inflammation","volume":"368","author":"Hekim","year":"2015","journal-title":"Cancer Lett."},{"issue":"4","key":"10.1016\/j.pscia.2026.100125_bib100","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/09553002.2018.1440092","article-title":"Mechanisms of inflammatory responses to radiation and normal tissues toxicity: clinical implications","volume":"94","author":"Najafi","year":"2018","journal-title":"Int. J. Radiat. Biol."},{"issue":"16","key":"10.1016\/j.pscia.2026.100125_bib101","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1007\/s00018-020-03479-x","article-title":"Targets for protection and mitigation of radiation injury","volume":"77","author":"Khodamoradi","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.pscia.2026.100125_bib102","article-title":"Radiation-induced inflammation and autoimmune diseases","volume":"5","author":"Yahyapour","year":"2018","journal-title":"Milit. Med. Res."},{"issue":"1","key":"10.1016\/j.pscia.2026.100125_bib103","doi-asserted-by":"crossref","DOI":"10.15190\/d.2015.27","article-title":"NF-\u03baB as a key player in regulation of cellular radiation responses and identification of radiation countermeasures","volume":"3","author":"Singh","year":"2015","journal-title":"Discoveries"},{"key":"10.1016\/j.pscia.2026.100125_bib104","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.toxlet.2015.10.010","article-title":"Conceptual approaches for treatment of phosgene inhalation-induced lung injury","volume":"244","author":"Holmes","year":"2016","journal-title":"Toxicol. Lett."},{"issue":"1","key":"10.1016\/j.pscia.2026.100125_bib105","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41391-023-00666-2","article-title":"PCPro: a clinically accessible, circulating lipid biomarker signature for poor-prognosis metastatic prostate cancer","volume":"27","author":"Scheinberg","year":"2024","journal-title":"Prostate Cancer Prostatic Dis."}],"updated-by":[{"DOI":"10.1016\/j.pscia.2026.100154","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000}}],"container-title":["Pharmaceutical Science Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2773216926000188?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2773216926000188?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T10:06:56Z","timestamp":1783159616000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2773216926000188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":105,"alternative-id":["S2773216926000188"],"URL":"https:\/\/doi.org\/10.1016\/j.pscia.2026.100125","relation":{},"ISSN":["2773-2169"],"issn-type":[{"value":"2773-2169","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic potential of the sphingosine kinase 2 inhibitor opaganib","name":"articletitle","label":"Article Title"},{"value":"Pharmaceutical Science Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pscia.2026.100125","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Shandong University.","name":"copyright","label":"Copyright"}],"article-number":"100125"}}